Compare SGRP & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRP | PMN |
|---|---|---|
| Founded | 1967 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 23.5M |
| IPO Year | 1996 | N/A |
| Metric | SGRP | PMN |
|---|---|---|
| Price | $0.89 | $7.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | ★ 61.0K | 39.2K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,130,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.79 | N/A |
| 52 Week Low | $0.85 | $6.27 |
| 52 Week High | $2.28 | $39.75 |
| Indicator | SGRP | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 95.95 |
| Support Level | $0.87 | $0.29 |
| Resistance Level | $0.92 | $7.95 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | -0.01 | 0.85 |
| Stochastic Oscillator | 16.35 | 92.24 |
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.